Abstract:Purpose: Resveratrol is a natural polyphenol which has a very low bioavailability but whose antioxidant, anti-inflammatory and anti-apoptotic properties may have therapeutic potential for the treatment of neurodegenerative diseases such as multiple sclerosis (MS). Previously, we reported the oral administration of resveratrol nanoparticles (RNs) elicited a neuroprotective effect in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, at significantly lower doses than unconjugated resveratrol (RSV) due to enhanced bioavailability. Furthermore, we demonstrated that the intranasal administration of a cell-derived secretome-based therapy at low concentrations leads to the selective neuroprotection of the optic nerve in EAE mice. The current study sought to assess the potential selective efficacy of lower concentrations of intranasal RNs for attenuating optic nerve damage in EAE mice. Methods: EAE mice received either a daily intranasal vehicle, RNs or unconjugated resveratrol (RSV) for a period of thirty days beginning on the day of EAE induction. Mice were assessed daily for limb paralysis and weekly for visual function using the optokinetic response (OKR) by observers masked to treatment regimes. After sacrifice at day 30, spinal cords and optic nerves were stained to assess inflammation and demyelination, and retinas were immunostained to quantify retinal ganglion cell (RGC) survival. Results: Intranasal RNs significantly increased RGC survival at half the dose previously shown to be required when given orally, reducing the risk of systemic side effects associated with prolonged use. Both intranasal RSV and RN therapies enhanced RGC survival trends, however, only the effects of intranasal RNs were significant. RGC loss was prevented even in the presence of inflammatory and demyelinating changes induced by EAE in optic nerves. Conclusions: The intranasal administration of RNs is able to reduce RGC loss independent of the inflammatory and demyelinating effects on the optic nerve and the spinal cord. The concentration of RNs needed to achieve neuroprotection is lower than previously demonstrated with oral administration, suggesting intranasal drug delivery combined with nanoparticle conjugation warrants further exploration as a potential neuroprotective strategy for the treatment of optic neuritis, alone as well as in combination with glucocorticoids.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether resveratrol nanoparticles (RNs) can reduce the loss of retinal ganglion cells (RGCs) in the optic nerve through the intranasal administration route in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS), and whether this effect is independent of inflammation and demyelination. Specifically, the researchers hope to verify whether intranasally administered RNs can provide a neuroprotective effect at a lower dose while reducing the risk of systemic side effects. ### Research Background and Objectives Multiple sclerosis (MS) is a demyelinating inflammatory disease of the central nervous system (CNS), often manifested as optic neuritis, leading to permanent vision loss. Current treatment methods mainly focus on reducing inflammation, but have limited therapeutic effects on neurodegeneration. Resveratrol (RSV) is a natural polyphenol with antioxidant, anti - inflammatory and anti - apoptotic properties, and may have therapeutic potential for neurodegenerative diseases. However, the bioavailability of RSV is very low, which limits its clinical application. ### Previous Research Previous research by the research team has shown that orally administered resveratrol nanoparticles (RNs) can significantly reduce the loss of RGCs in the EAE mouse model and reduce the severity of neurological dysfunction, with a required dose being only one - sixth of that of unbound RSV. In addition, they also found that intranasally administered cell - derived secretome therapy can selectively protect RGCs in the optic nerve at low concentrations. ### Current Research Objectives The current research aims to evaluate whether intranasally administered low - concentration RNs can effectively reduce the loss of RGCs in the optic nerve of EAE mice. The research hypothesis is that intranasally administered RNs can reduce the required resveratrol dose, thereby increasing the neuroprotective effect while reducing the risk of systemic side effects. ### Methods EAE mice received intranasally administered vehicle, RNs or unbound RSV daily starting from the day of EAE induction for 30 days. The researchers evaluated the treatment effect by the following methods: - Observing limb paralysis daily - Evaluating visual function using the optokinetic response (OKR) weekly - After 30 days, sacrificing the mice and staining to detect inflammation and demyelination in the spinal cord and optic nerve, as well as the survival of RGCs in the retina ### Results - Intranasal administration of 8.44 mg/kg RNs significantly increased the survival rate of RGCs, with a dose being only half of that required for oral administration. - 1.27 mg/kg RNs and the same dose of RSV also showed a trend of increasing RGC survival, but not significantly. - The neuroprotective effect of RNS is independent of inflammation and demyelination changes. - Intranasally administered RNs did not significantly change the inflammation and demyelination in the optic nerve and spinal cord, nor did it significantly improve visual function. ### Conclusions Intranasally administered RNs can reduce the loss of RGCs in the optic nerve of EAE mice at a lower dose, and this effect is independent of inflammation and demyelination. This indicates that intranasal administration combined with a nanoparticle delivery system is worthy of further exploration as a potential neuroprotective strategy for treating optic neuritis, especially when combined with glucocorticoids, it may provide a synergistic treatment effect.

Intranasal Resveratrol Nanoparticles Enhance Neuroprotection in a Model of Multiple Sclerosis